US Stock MarketDetailed Quotes

PPBT Purple Biotech

Watchlist

3.355
+0.105+3.23%

Close Nov 29 13:00 ET

3.420
+0.065+1.93%

Post 17:01 ET

5.25MMarket Cap0.45P/E (TTM)

Purple Biotech Stock Forum

Anakari

Nov 29 00:15

$Purple Biotech (PPBT.US)$ comeback 🔝🔝

Stock_Drift

Nov 27 10:22

Low Floats. 11:21am 11/27

$Draganfly (DPRO.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $Alaunos Therapeutics (TCRT.US)$ $Purple Biotech (PPBT.US)$ $Homestolife (HTLM.US)$ $Pulmatrix (PULM.US)$ $SCWorx (WORX.US)$ $Interactive Strength (TRNR.US)$ $Infobird Software (IFBD.US)$ $Cyclerion Therapeutics (CYCN.US)$ $IM Cannabis (IMCC.US)$ $Unusual Machines (UMAC.US)$ $VCI Global (VCIG.US)$
📊⚡️📊

Stock_Drift

Nov 15 06:06

$Purple Biotech (PPBT.US)$

Trytosaveabit

Nov 4 06:52

Update

$Purple Biotech (PPBT.US)$ Reuters· 1 min ago
Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death!
Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results

Trytosaveabit

Oct 25 06:50

Update

$Purple Biotech (PPBT.US)$ Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK
Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics

CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo model; A dose dependent activity and a synergistic effect of the engager arms also seen in non-small cell lung cancer patient-derived explants

Lead tribody IM1240 data demonstrated...